Canaccord Genuity Reiterates Buy Rating on Kymera Therapeutics
Canaccord Genuity maintains its positive outlook on Kymera Therapeutics, setting a $129 price target, a 18% upside from the current price.
Key Points
- Canaccord Genuity reiterated its buy rating on Kymera Therapeutics (NasdaqGM: KYMR) with a target price of $129, as of June 26, 2026.
- Canaccord Genuity's $129 price target implies 18% upside from Kymera Therapeutics, Inc.'s ($KYMR) current $109.32 share price.
- Shares of Kymera Therapeutics traded near $116.46 on Friday, with a market cap of approximately $9.58 billion and a 52-week high of $130.05.
- Kymera Therapeutics is a biotech firm developing treatments for various diseases, with a strong institutional backing and multiple analysts maintaining buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Canaccord Genuity reiterated its buy rating on Kymera Therapeutics, Inc. (NasdaqGM: KYMR) on June 26, 2026. The firm set a price target of $129. Shares of Kymera traded around $116.46 on Friday.
Canaccord Genuity vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Kymera Therapeutics, Inc. Stock Down 7.5%
Shares of Kymera Therapeutics traded near $116.46 on Friday. The company has a market cap of about $9.58 billion and a forward P/E ratio that is not meaningful as it isn't profitable. With a beta of 2.027, the stock shows higher volatility than the market. The 52-week range is between $36.65 and $130.05, and the stock's 50-day and 200-day moving averages are $84.33 and $74.76, respectively. Kymera maintains a strong liquidity position with a current ratio of 10.81 and a quick ratio of 10.39.
$KYMR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 26, 2026, Canaccord Genuity maintained its buy rating on Kymera Therapeutics, setting a price target of $129. BTIG also reiterated its buy rating with a target of $134 on June 25, 2026. The consensus among analysts is a strong buy, with an average target price of $119.19 based on 21 analyst opinions.
Insider Buying and Selling at Kymera Therapeutics, Inc.
On June 25, 2026, Bruce Booth sold 548,321 shares at an average price of $118.76 under a Rule 10b5-1 plan. On the same day, Noah Goodman, Chief Business Officer, sold 5,000 shares at $114.00, also under a planned sale. Goodman purchased 5,000 shares at $21.05 in an unplanned transaction.
Other Institutional Activity in Kymera Therapeutics
FMR LLC increased its holdings by 2,771,376 shares, bringing its total to 11,699,950 shares worth approximately $974.49 million. T. Rowe Price Investment Management, Inc. made a significant addition, boosting its stake by 4,835,252 shares to a total of 5,464,997 shares valued at about $455.18 million, marking a 767.8% increase. Meanwhile, Price T Rowe Associates Inc /MD/ reduced its position by 98,488 shares, holding 6,060,847 shares worth $504.81 million.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a biotechnology company based in Watertown, Massachusetts. It focuses on developing small molecule drugs that degrade disease-causing proteins. The company is working on treatments for conditions like atopic dermatitis, autoimmune diseases, and various cancers. Under the leadership of CEO Dr. Nello Mainolfi, Kymera employs 253 people and collaborates with Sanofi S.A. on certain drug candidates.
Bottom Line
Kymera Therapeutics continues to garner positive analyst attention, with Canaccord Genuity maintaining a buy rating and a $129 target. The company's innovative approach to drug development and strong institutional support make it a noteworthy player in the biotech sector. Keep in mind, 13F filings and analyst ratings are backward-looking and may not reflect the latest market conditions.
Get Kymera Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KYMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.